19 Geographic Atrophy Clinical Trials in Pittsburgh, PA (2026)

Q: How do I join a clinical trial in Pittsburgh?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Pittsburgh research site will contact you.

Recruiting Geographic Atrophy Studies in Pittsburgh

NCT00078078Recruiting

Clinical and Laboratory Study of Methylmalonic Acidemia

Methylmalonic acidemia (MMA), one of the most common inborn errors of organic acid metabolism, is heterogeneous in etiology and clinical manifestations. Affected patients with cblA, cblB and mut class...

Pittsburgh, PA2,275 participantsNational Human Genome Research Institute (NHGRI)

View Study Details

NCT01163578Recruiting

Biomarkers in Transplant Recipients to Improve Outcomes

The objective of this study is to evaluate whether certain proteins, expressed in biological tissues can indict a better understanding of the effect of drugs that are used to treat rejection, and of p...

Pittsburgh, PA1,200 participantsUniversity of Pittsburgh

View Study Details

NCT05947071Recruiting

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

Influenza virus is a significant pathogen in pediatric solid organ transplant (SOT) recipients. However, these individuals respond poorly to standard-dose (SD) inactivated influenza vaccine (IIV). Rec...

Pittsburgh, PA312 participantsNational Institute of Allergy and Infectious Diseases (NIAID)

View Study Details

NCT05482893Recruiting

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and prelimi...

Pittsburgh, PA258 participantsPhanes Therapeutics

View Study Details

NCT06445972Recruiting

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, ...

Pittsburgh, PA210 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06709521Recruiting

Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)

The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of m...

Pittsburgh, PA200 participantsNational Institute of Allergy and Infectious Diseases (NIAID)

View Study Details

NCT06022029Recruiting

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expan...

Pittsburgh, PA168 participantsOncoNano Medicine, Inc.

View Study Details

NCT05702229Recruiting

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participant...

Pittsburgh, PA163 participantsAstraZeneca

View Study Details

NCT06469944Recruiting

Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of sacituzumab tirumotecan with pembrolizumab and fluoropyrimidine chemotherapy for ...

Pittsburgh, PA160 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06569693Recruiting

Dyadic Sleep Study

The purpose of this study is to learn about sleep behaviors and test different ways to help patients with cancer and caregiver partners....

Pittsburgh, PA152 participantsUniversity of Miami

View Study Details

NCT02945579Recruiting

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

This clinical trial studies eliminating surgery and/or radiation therapy in treating breast cancer patients. In HER2 positive and triple negative breast cancers, after systemic therapy, when image-gui...

Pittsburgh, PA120 participantsM.D. Anderson Cancer Center

View Study Details

NCT03539822Recruiting

Cabozantinib Plus Durvalumab with or Without Tremelimumab in Patients with Gastroesophageal Cancer and Other Gastrointestinal Malignancies

The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies ...

Pittsburgh, PA117 participantsAnwaar Saeed

View Study Details

NCT07069712Recruiting

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants ...

Pittsburgh, PA100 participantsAstraZeneca

View Study Details

NCT04829058Recruiting

GYNEMESH PS Mesh Post Marketing Clinical Follow-Up Study

The objective of this retrospective and prospective, single-arm, observational, multicenter, post-market study is to evaluate outcomes in women who underwent surgery for vaginal or uterine prolapse wi...

Pittsburgh, PA100 participantsEthicon, Inc.

View Study Details

NCT07332975Recruiting

ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC

This translational biomarker study will collect blood in patients Stage I triple negative breast cancer at diagnosis prior to either neoadjuvant treatment or surgery and then during treatment....

Pittsburgh, PA77 participantsUniversity of Pittsburgh

View Study Details

NCT06648759Recruiting

Vagal Stimulator to Reduce Nasogastric Tube Use

Abdominal surgery, laparoscopic or open, is frequently performed at UPMC Shadyside hospital. One of the most frequent complications following abdominal surgery is a postoperative ileus. Although posto...

Pittsburgh, PA60 participantsJacques E. Chelly

View Study Details

NCT07475286Recruiting

Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis

This trial will administer laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) to patients with peritoneal carcinomatosis from gastric cancer (GPC) who are receiving standard of care system...

Pittsburgh, PA22 participantsMohammad Haroon Asif Choudry

View Study Details

NCT07001592Recruiting

Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

This research study aims to evaluate the safety and determine the optimal dose of a new experimental drug, vvDD-hIL2 (vaccinia virus double-deleted human interleukin 2), in patients with advanced abdo...

Pittsburgh, PA18 participantsAllegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

View Study Details

NCT07439887Recruiting

Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease

A Phase 1/2, open-label, non-randomized, dose-escalation study, where a minimum of 9 and a maximum of 18 eligible patients with Stargardt Disease will be enrolled sequentially in up to 3 dose cohorts ...

Pittsburgh, PA18 participantsRay Therapeutics, Inc.

View Study Details

About Geographic Atrophy Clinical Trials in Pittsburgh

Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.

There are currently 19 geographic atrophy clinical trials recruiting participants in Pittsburgh, PA. These studies are seeking a combined 5,730 participants. Research is being sponsored by National Human Genome Research Institute (NHGRI), University of Pittsburgh, National Institute of Allergy and Infectious Diseases (NIAID) and 12 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Geographic Atrophy Clinical Trials in Pittsburgh — FAQ

Are there geographic atrophy clinical trials in Pittsburgh?

Yes, there are 19 geographic atrophy clinical trials currently recruiting in Pittsburgh, PA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Pittsburgh?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Pittsburgh research site will contact you about next steps.

Are clinical trials in Pittsburgh free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Pittsburgh studies also compensate for your time and travel.

What geographic atrophy treatments are being tested?

The 19 active trials in Pittsburgh are testing new therapies including novel drugs, biologics, and treatment approaches for geographic atrophy.

Data updated July 13, 2026 from ClinicalTrials.gov